Recent advances in cancer therapeutics have shown that identifying molecular targets for lung cancer treatment such as vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is important to improve patient survival. This evidence concerns the gene VEGFA and cancer.